Bioceres Crop Solutions Corp. (BIOX)
BIOX Stock Price Chart
Explore Bioceres Crop Solutions Corp. interactive price chart. Choose custom timeframes to analyze BIOX price movements and trends.
BIOX Company Profile
Discover essential business fundamentals and corporate details for Bioceres Crop Solutions Corp. (BIOX) to support your stock research and investment decisions.
Sector
Basic Materials
Industry
Agricultural Inputs
IPO Date
22 Mar 2018
Employees
400.00
Website
https://biocerescrops.comCEO
Federico Trucco
Description
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.
BIOX Financial Timeline
Browse a chronological timeline of Bioceres Crop Solutions Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Nov 2025
EPS estimate is -$0.04, while revenue estimate is $90.23M.
Earnings released on 21 May 2025
EPS came in at -$0.02 surpassing the estimated -$0.10 by +80.00%, while revenue for the quarter reached $59.60M , missing expectations by -46.71%.
Earnings released on 11 Feb 2025
EPS came in at $0.01 falling short of the estimated $0.14 by -92.86%, while revenue for the quarter reached $106.80M , beating expectations by +72.63%.
Earnings released on 27 Nov 2024
EPS came in at -$0.09 , while revenue for the quarter reached $92.60M .
Earnings released on 11 Nov 2024
EPS came in at -$0.09 falling short of the estimated -$0.01 by -800.00%, while revenue for the quarter reached $124.31M , missing expectations by -13.11%.
Earnings released on 29 May 2024
EPS came in at $0.14 falling short of the estimated $0.17 by -17.65%, while revenue for the quarter reached $84.00M , missing expectations by -36.56%.
Earnings released on 8 Feb 2024
EPS came in at $0.02 falling short of the estimated $0.09 by -77.78%, while revenue for the quarter reached $140.30M , beating expectations by +19.92%.
Earnings released on 13 Nov 2023
EPS came in at -$0.07 falling short of the estimated $0.11 by -163.64%, while revenue for the quarter reached $116.18M , missing expectations by -6.17%.
Earnings released on 11 Sept 2023
EPS came in at -$0.06 falling short of the estimated $0.05 by -220.00%, while revenue for the quarter reached $105.07M , missing expectations by -2.40%.
Earnings released on 10 May 2023
EPS came in at $0.44 surpassing the estimated $0.02 by +1.79K%, while revenue for the quarter reached $92.98M , missing expectations by -17.58%.
Earnings released on 8 Feb 2023
EPS came in at -$0.14 falling short of the estimated $0.16 by -187.50%, while revenue for the quarter reached $94.55M , beating expectations by +2.80%.
Earnings released on 29 Nov 2022
EPS came in at $0.01 falling short of the estimated $0.05 by -80.00%, while revenue for the quarter reached $126.84M , beating expectations by +54.70%.
Earnings released on 30 Jun 2022
EPS came in at -$0.11 , while revenue for the quarter reached $101.56M .
Earnings released on 27 May 2022
EPS came in at -$0.16 falling short of the estimated -$0.11 by -45.45%, while revenue for the quarter reached $68.23M , beating expectations by +52.90%.
Earnings released on 25 Feb 2022
EPS came in at $0.08 surpassing the estimated $0.05 by +60.00%, while revenue for the quarter reached $92.31M , beating expectations by +31.93%.
Earnings released on 30 Nov 2021
EPS came in at $0.02 falling short of the estimated $0.09 by -77.78%, while revenue for the quarter reached $66.35M , beating expectations by +6.32%.
Earnings released on 30 Jun 2021
EPS came in at $0.02 , while revenue for the quarter reached $81.05M .
Earnings released on 28 May 2021
EPS came in at -$0.03 falling short of the estimated -$0.02 by -37.99%, while revenue for the quarter reached $35.54M , missing expectations by -20.63%.
Earnings released on 26 Feb 2021
EPS came in at $0.02 falling short of the estimated $0.36 by -94.44%, while revenue for the quarter reached $48.00M , missing expectations by -42.86%.
Earnings released on 30 Nov 2020
EPS came in at -$0.19 falling short of the estimated $0.08 by -337.50%, while revenue for the quarter reached $42.11M .
Earnings released on 28 Sept 2020
EPS came in at $0.06 falling short of the estimated $0.22 by -72.73%, while revenue for the quarter reached $48.13M .
BIOX Stock Performance
Access detailed BIOX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.